Ilebopride

{{Drugbox | Verifiedfields = changed | verifiedrevid = 477318123 | IUPAC_name = 4-amino-5-chloro-N-[[2-(diethylamino)ethyl]methyl]-2-methoxybenzamide | image = | width = | alt = | image2 = | width2 = | alt2 = | tradename = | Drugs.com = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number = 123456-78-9 | ATC_prefix = | ATC_suffix = | PubChem = 123456 | DrugBank = | ChemSpiderID = 123456 | UNII = | KEGG = | ChEBI = | ChEMBL = | synonyms = | C=18 | H=28 | Cl=1 | N=3 | O=2 | smiles = | InChI = | InChIKey = }}

Ilebopride is a chemical compound that has been studied for its potential use as a pharmaceutical drug. It is classified as a benzamide derivative and is primarily investigated for its effects on the central nervous system.

Pharmacology

Ilebopride acts as a selective antagonist of the dopamine D2 receptor. This receptor is a subtype of dopamine receptor that is involved in various neurological processes, including motor control, motivation, and reward. By blocking the D2 receptor, ilebopride may influence these processes, which has implications for the treatment of disorders such as schizophrenia and Parkinson's disease.

Mechanism of Action

The primary mechanism of action of ilebopride is its antagonistic effect on the dopamine D2 receptor. This action reduces the activity of dopamine in the brain, which can help alleviate symptoms of disorders characterized by excessive dopaminergic activity. In conditions like schizophrenia, where there is often an overactivity of dopamine pathways, D2 antagonists can help reduce symptoms such as hallucinations and delusions.

Clinical Research

Research on ilebopride is still in the experimental stages. Initial studies have focused on its pharmacokinetics, safety profile, and potential therapeutic effects. Animal studies have shown that ilebopride can cross the blood-brain barrier and exert its effects on the central nervous system. However, more research is needed to determine its efficacy and safety in humans.

Potential Applications

Ilebopride's primary potential application is in the treatment of psychiatric and neurological disorders. Its ability to modulate dopaminergic activity makes it a candidate for treating conditions such as:

• Schizophrenia
• Bipolar disorder
• Parkinson's disease

Side Effects

As with other dopamine antagonists, ilebopride may have side effects related to its action on the central nervous system. These can include:

• Extrapyramidal symptoms (e.g., tremors, rigidity)
• Sedation
• Weight gain
• Metabolic changes

Regulatory Status

As of the latest updates, ilebopride has not been approved for clinical use by major regulatory agencies such as the Food and Drug Administration (FDA) or the European Medicines Agency (EMA). It remains a compound of interest in research settings.

Also see

• Dopamine receptor antagonist
• Antipsychotic
• Neurotransmitter
• Central nervous system